BrainStorm Therapeutics is pioneering a revolutionary approach to treating neurological disorders that affect over a billion people worldwide. The San Diego startup combines AI-powered drug discovery with organoid technology—creating miniature 3D brain cell structures from patient stem cells—to accelerate the development of treatments for conditions ranging from Alzheimer’s to rare neurological diseases. This “lab in the loop” methodology, where AI and laboratory experiments inform each other, represents a significant advancement in addressing the brain’s complex biology and could dramatically reduce the 93% failure rate of neurological drug candidates in clinical trials.
The big picture: BrainStorm Therapeutics is using a hybrid approach combining AI and brain organoids to develop treatments for neurological disorders that affect over a billion people globally.
- The company’s “lab in the loop” method uses tiny 3D bundles of brain cells created from patient stem cells alongside AI models to accelerate drug discovery.
- This approach aims to solve a critical problem in neurological medicine, where over 93% of drug candidates currently fail during clinical trials.
What they’re saying: Scientists behind the venture believe this combination of technologies could finally crack the code of the brain’s complex biology.
- “The brain is the last frontier in modern biology,” explained Robert Fremeau, BrainStorm’s founder and CEO and former scientific director in neuroscience at Amgen.
- “By combining our organoid disease models with the power of generative AI, we now have the ability to start to unravel the underlying complex biology of disease networks.”
How it works: BrainStorm’s technology creates personalized brain cell models that can accurately represent specific neurological conditions while using AI to identify potential treatments.
- The company develops organoids – miniature 3D structures of brain cells – derived from patient stem cells that mimic specific disease states.
- These living models are paired with NVIDIA’s BioNeMo generative AI platform to identify promising drug candidates by analyzing patterns in biological data.
- The iterative process allows experimental results to continuously refine AI predictions, creating a feedback loop that improves accuracy over time.
Why this matters: The approach could revolutionize treatment development for neurological conditions by making it faster and more economically viable to develop therapies for both common and rare disorders.
- Traditional drug development for brain diseases is particularly challenging due to the complexity of the central nervous system and limited access to living brain tissue.
- By identifying therapeutics that can be applied to multiple diseases, BrainStorm could create economically viable treatments for rare conditions that might otherwise be neglected.
Behind the innovation: BrainStorm leverages cutting-edge computational technology to process the complex biological data needed for drug discovery.
- The company uses NVIDIA’s accelerated computing platforms and AI models trained on biological data to identify patterns in disease networks.
- BrainStorm is also working with the CURE5 Foundation, which is developing a resource-sharing platform to help researchers studying rare neurological disorders.
Recent Stories
DOE fusion roadmap targets 2030s commercial deployment as AI drives $9B investment
The Department of Energy has released a new roadmap targeting commercial-scale fusion power deployment by the mid-2030s, though the plan lacks specific funding commitments and relies on scientific breakthroughs that have eluded researchers for decades. The strategy emphasizes public-private partnerships and positions AI as both a research tool and motivation for developing fusion energy to meet data centers' growing electricity demands. The big picture: The DOE's roadmap aims to "deliver the public infrastructure that supports the fusion private sector scale up in the 2030s," but acknowledges it cannot commit to specific funding levels and remains subject to Congressional appropriations. Why...
Oct 17, 2025Tying it all together: Credo’s purple cables power the $4B AI data center boom
Credo, a Silicon Valley semiconductor company specializing in data center cables and chips, has seen its stock price more than double this year to $143.61, following a 245% surge in 2024. The company's signature purple cables, which cost between $300-$500 each, have become essential infrastructure for AI data centers, positioning Credo to capitalize on the trillion-dollar AI infrastructure expansion as hyperscalers like Amazon, Microsoft, and Elon Musk's xAI rapidly build out massive computing facilities. What you should know: Credo's active electrical cables (AECs) are becoming indispensable for connecting the massive GPU clusters required for AI training and inference. The company...
Oct 17, 2025Vatican launches Latin American AI network for human development
The Vatican hosted a two-day conference bringing together 50 global experts to explore how artificial intelligence can advance peace, social justice, and human development. The event launched the Latin American AI Network for Integral Human Development and established principles for ethical AI governance that prioritize human dignity over technological advancement. What you should know: The Pontifical Academy of Social Sciences, the Vatican's research body for social issues, organized the "Digital Rerum Novarum" conference on October 16-17, combining academic research with practical AI applications. Participants included leading experts from MIT, Microsoft, Columbia University, the UN, and major European institutions. The conference...